drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00197 | DB08882 | 1,324 | 1,281 | [
"DDInter1881",
"DDInter1070"
] | Troglitazone | Linagliptin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1324,
24,
1281
]
],
[
[
1324,
23,
1103
],
[
1103,
23,
1281
]
],
[
[
1324,
24,
1060
],
[
1060,
63,
1281
]
],
[
[
1324,
24,
1529
],
[
15... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[... | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin a... |
DB00373 | DB00959 | 461 | 1,486 | [
"DDInter1809",
"DDInter1191"
] | Timolol | Methylprednisolone | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
461,
24,
1486
]
],
[
[
461,
24,
175
],
[
175,
40,
1486
]
],
[
[
461,
24,
167
],
[
167,
1,
1486
]
],
[
[
461,
6,
4973
],
[
4973,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methyl... |
DB00532 | DB08870 | 208 | 850 | [
"DDInter1152",
"DDInter228"
] | Mephenytoin | Brentuximab vedotin | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
208,
24,
850
]
],
[
[
208,
24,
267
],
[
267,
24,
850
]
],
[
[
208,
24,
1583
],
[
1583,
63,
850
]
],
[
[
208,
63,
134
],
[
134,
2... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab ... |
DB01059 | DB01611 | 956 | 1,487 | [
"DDInter1313",
"DDInter893"
] | Norfloxacin | Hydroxychloroquine | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
956,
25,
1487
]
],
[
[
956,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
956,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
956,
63,
663
],
[
663,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"... | Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Norfloxacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compo... |
DB00261 | DB00363 | 702 | 695 | [
"DDInter93",
"DDInter419"
] | Anagrelide | Clozapine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
702,
25,
695
]
],
[
[
702,
25,
1178
],
[
1178,
1,
695
]
],
[
[
702,
25,
623
],
[
623,
40,
695
]
],
[
[
702,
24,
867
],
[
867,
1,... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
... | Anagrelide may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Clozapine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Quetiapine and Quetiapine (Compound) resembles Clozapine (Compound)
Anagrelide may cause a... |
DB00030 | DB00618 | 1,685 | 1,572 | [
"DDInter934",
"DDInter498"
] | Insulin human | Demeclocycline | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Moderate | 1 | [
[
[
1685,
24,
1572
]
],
[
[
1685,
24,
1620
],
[
1620,
1,
1572
]
],
[
[
1685,
24,
1669
],
[
1669,
40,
1572
]
],
[
[
1685,
24,
1680
],
[
168... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Demecl... |
DB01320 | DB08816 | 651 | 578 | [
"DDInter783",
"DDInter1802"
] | Fosphenytoin | Ticagrelor | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
651,
25,
578
]
],
[
[
651,
6,
8374
],
[
8374,
45,
578
]
],
[
[
651,
21,
28645
],
[
28645,
60,
578
]
],
[
[
651,
25,
1135
],
[
1135,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tic... | Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Fosphenytoin (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Fosphenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a ... |
DB01035 | DB06699 | 1,401 | 774 | [
"DDInter1524",
"DDInter493"
] | Procainamide | Degarelix | A derivative of procaine with less CNS action. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
1401,
25,
774
]
],
[
[
1401,
64,
521
],
[
521,
1,
774
]
],
[
[
1401,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1401,
62,
112
],
[
112,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} ... | Procainamide may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Procainamide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Procainamide may cause a minor interaction that can limit c... |
DB00208 | DB06605 | 1,018 | 1,409 | [
"DDInter1804",
"DDInter108"
] | Ticlopidine | Apixaban | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1018,
25,
1409
]
],
[
[
1018,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
1018,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
1018,
23,
539
],
[
53... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaba... | Ticlopidine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Ticlopidine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicu... |
DB00467 | DB00970 | 1,467 | 0 | [
"DDInter644",
"DDInter466"
] | Enoxacin | Dactinomycin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Minor | 0 | [
[
[
1467,
23,
0
]
],
[
[
1467,
7,
5178
],
[
5178,
57,
0
]
],
[
[
1467,
6,
3199
],
[
3199,
57,
0
]
],
[
[
1467,
18,
4930
],
[
4930,
5... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dactinomycin"
]
],
[
[
"Enoxacin",
"{u} (Compound) upregulates {v} (Gene)",
"XBP1"
],
[
"XBP1",
"{u} (Gene) is downregulated by {v} (Compo... | Enoxacin (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Dactinomycin (Compound)
Enoxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Dactinomycin (Compound)
Enoxacin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Dactinomycin (Compound)
Enoxacin (Co... |
DB08827 | DB09143 | 990 | 313 | [
"DDInter1085",
"DDInter1701"
] | Lomitapide | Sonidegib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
990,
24,
313
]
],
[
[
990,
63,
1194
],
[
1194,
23,
313
]
],
[
[
990,
64,
478
],
[
478,
24,
313
]
],
[
[
990,
63,
578
],
[
578,
2... | [
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
... | Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Lomitapide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a mod... |
DB01367 | DB09074 | 1,163 | 1,362 | [
"DDInter1572",
"DDInter1327"
] | Rasagiline | Olaparib | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1163,
24,
1362
]
],
[
[
1163,
63,
491
],
[
491,
24,
1362
]
],
[
[
1163,
25,
1619
],
[
1619,
63,
1362
]
],
[
[
1163,
24,
985
],
[
985,
... | [
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],... | Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Rasagiline may lead to a major life threatening interaction when taken with Rucaparib and Ru... |
DB01218 | DB12141 | 1,493 | 971 | [
"DDInter852",
"DDInter817"
] | Halofantrine | Gilteritinib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
1493,
25,
971
]
],
[
[
1493,
62,
1247
],
[
1247,
23,
971
]
],
[
[
1493,
64,
485
],
[
485,
24,
971
]
],
[
[
1493,
25,
730
],
[
730,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"... | Halofantrine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Halofantrine may lead to a major life threatening interaction when taken with Pentamidine and Pentam... |
DB00047 | DB14509 | 176 | 1,399 | [
"DDInter932",
"DDInter1081"
] | Insulin glargine | Lithium carbonate | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
176,
24,
1399
]
],
[
[
176,
24,
964
],
[
964,
23,
1399
]
],
[
[
176,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
176,
23,
274
],
[
274,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycl... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Se... |
DB06441 | DB06779 | 936 | 365 | [
"DDInter283",
"DDInter470"
] | Cangrelor | Dalteparin | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
936,
25,
365
]
],
[
[
936,
23,
539
],
[
539,
62,
365
]
],
[
[
936,
63,
305
],
[
305,
24,
365
]
],
[
[
936,
24,
1496
],
[
1496,
6... | [
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Cangrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Cangrelor may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli a... |
DB01234 | DB12825 | 1,220 | 1,375 | [
"DDInter513",
"DDInter1032"
] | Dexamethasone | Lefamulin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
1220,
25,
1375
]
],
[
[
1220,
24,
159
],
[
159,
63,
1375
]
],
[
[
1220,
24,
309
],
[
309,
24,
1375
]
],
[
[
1220,
25,
976
],
[
976,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"La... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilon... |
DB00333 | DB08895 | 576 | 976 | [
"DDInter1166",
"DDInter1825"
] | Methadone | Tofacitinib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
576,
24,
976
]
],
[
[
576,
40,
307
],
[
307,
23,
976
]
],
[
[
576,
24,
214
],
[
214,
63,
976
]
],
[
[
576,
25,
982
],
[
982,
63,... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor inte... | Methadone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could ... |
DB00222 | DB12130 | 245 | 1,017 | [
"DDInter825",
"DDInter1094"
] | Glimepiride | Lorlatinib | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
245,
24,
1017
]
],
[
[
245,
24,
1101
],
[
1101,
23,
1017
]
],
[
[
245,
24,
175
],
[
175,
24,
1017
]
],
[
[
245,
40,
1411
],
[
1411,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Tri... |
DB00513 | DB13151 | 191 | 1,380 | [
"DDInter70",
"DDInter101"
] | Aminocaproic acid | Anti-inhibitor coagulant complex | An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. | Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors. | Major | 2 | [
[
[
191,
25,
1380
]
],
[
[
191,
6,
6798
],
[
6798,
45,
335
],
[
335,
25,
1380
]
],
[
[
191,
54,
19279
],
[
19279,
15,
335
],
[
335,
25,
... | [
[
[
"Aminocaproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anti-inhibitor coagulant complex"
]
],
[
[
"Aminocaproic acid",
"{u} (Compound) binds {v} (Gene)",
"PLG"
],
[
"PLG",
"{u} (Gene) is bound by {... | Aminocaproic acid (Compound) binds PLG (Gene) and PLG (Gene) is bound by Tranexamic acid (Compound) and Tranexamic acid may lead to a major life threatening interaction when taken with Anti-inhibitor coagulant complex
Aminocaproic acid (Compound) is included by Decreased Fibrinolysis (Pharmacologic Class) and Decreased... |
DB00307 | DB15093 | 1,101 | 1,654 | [
"DDInter202",
"DDInter1698"
] | Bexarotene | Somapacitan | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Major | 2 | [
[
[
1101,
25,
1654
]
],
[
[
1101,
62,
608
],
[
608,
23,
1654
]
],
[
[
1101,
63,
176
],
[
176,
24,
1654
]
],
[
[
1101,
24,
1135
],
[
1135,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somapacitan"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insul... |
DB01015 | DB09054 | 1,247 | 384 | [
"DDInter1724",
"DDInter905"
] | Sulfamethoxazole | Idelalisib | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1247,
24,
384
]
],
[
[
1247,
23,
1618
],
[
1618,
24,
384
]
],
[
[
1247,
63,
305
],
[
305,
24,
384
]
],
[
[
1247,
62,
888
],
[
888,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Asparag... |
DB01169 | DB11986 | 57 | 484 | [
"DDInter120",
"DDInter648"
] | Arsenic trioxide | Entrectinib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
57,
25,
484
]
],
[
[
57,
62,
1247
],
[
1247,
23,
484
]
],
[
[
57,
64,
1539
],
[
1539,
24,
484
]
],
[
[
57,
25,
774
],
[
774,
24,... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Arsenic trioxide may lead to a major life threatening interaction when taken with Ofloxacin and O... |
DB00019 | DB00694 | 1,257 | 51 | [
"DDInter1405",
"DDInter485"
] | Pegfilgrastim | Daunorubicin | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1257,
24,
51
]
],
[
[
1257,
24,
1468
],
[
1468,
63,
51
]
],
[
[
1257,
24,
134
],
[
134,
24,
51
]
],
[
[
1257,
24,
57
],
[
57,
64... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and... |
DB08868 | DB08901 | 1,011 | 1,468 | [
"DDInter737",
"DDInter1492"
] | Fingolimod | Ponatinib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1011,
25,
1468
]
],
[
[
1011,
64,
478
],
[
478,
24,
1468
]
],
[
[
1011,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
1011,
21,
29271
],
[
29... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Fingolimod may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Fingolimod (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Fingolimod (Compound) causes Migraine... |
DB00014 | DB01224 | 521 | 623 | [
"DDInter839",
"DDInter1553"
] | Goserelin | Quetiapine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
521,
24,
623
]
],
[
[
521,
24,
827
],
[
827,
1,
623
]
],
[
[
521,
25,
695
],
[
695,
1,
623
]
],
[
[
521,
21,
29039
],
[
29039,
6... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Goserelin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Goserelin (Compound) ... |
DB00427 | DB01452 | 1,233 | 993 | [
"DDInter1879",
"DDInter532"
] | Triprolidine | Diamorphine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
1233,
24,
993
]
],
[
[
1233,
63,
421
],
[
421,
40,
993
]
],
[
[
1233,
63,
475
],
[
475,
25,
993
]
],
[
[
1233,
24,
13
],
[
13,
2... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening... |
DB06700 | DB06822 | 643 | 802 | [
"DDInter511",
"DDInter1812"
] | Desvenlafaxine | Tinzaparin | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
643,
24,
802
]
],
[
[
643,
64,
222
],
[
222,
24,
802
]
],
[
[
643,
40,
1100
],
[
1100,
24,
802
]
],
[
[
643,
63,
1432
],
[
1432,
... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Desvenlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"S... | Desvenlafaxine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Desvenlafaxine (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could ex... |
DB00773 | DB05773 | 896 | 1,047 | [
"DDInter702",
"DDInter1848"
] | Etoposide | Trastuzumab emtansine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
896,
24,
1047
]
],
[
[
896,
25,
375
],
[
375,
63,
1047
]
],
[
[
896,
24,
381
],
[
381,
63,
1047
]
],
[
[
896,
24,
1112
],
[
1112,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
... | Etoposide may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Sodium auro... |
DB00674 | DB09080 | 1,516 | 144 | [
"DDInter802",
"DDInter1331"
] | Galantamine | Olodaterol | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1516,
24,
144
]
],
[
[
1516,
24,
1011
],
[
1011,
24,
144
]
],
[
[
1516,
63,
11
],
[
11,
24,
144
]
],
[
[
1516,
24,
823
],
[
823,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Tore... |
DB01240 | DB08816 | 885 | 578 | [
"DDInter657",
"DDInter1802"
] | Epoprostenol | Ticagrelor | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
885,
24,
578
]
],
[
[
885,
6,
17955
],
[
17955,
45,
578
]
],
[
[
885,
21,
28646
],
[
28646,
60,
578
]
],
[
[
885,
63,
336
],
[
336,
... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Epoprostenol",
"{u} (Compound) binds {v} (Gene)",
"P2RY12"
],
[
"P2RY12",
"{u} (Gene) is bound by {v} (Compoun... | Epoprostenol (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) is bound by Ticagrelor (Compound)
Epoprostenol (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Epoprostenol may cau... |
DB01242 | DB09280 | 1,237 | 1,604 | [
"DDInter410",
"DDInter1101"
] | Clomipramine | Lumacaftor | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1237,
24,
1604
]
],
[
[
1237,
63,
1061
],
[
1061,
24,
1604
]
],
[
[
1237,
24,
292
],
[
292,
24,
1604
]
],
[
[
1237,
64,
593
],
[
593,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib a... |
DB00431 | DB00843 | 1,503 | 479 | [
"DDInter1072",
"DDInter583"
] | Lindane | Donepezil | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1503,
24,
479
]
],
[
[
1503,
21,
29232
],
[
29232,
60,
479
]
],
[
[
1503,
24,
678
],
[
678,
62,
479
]
],
[
[
1503,
24,
121
],
[
121,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {... | Lindane (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Donepezil (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine and Oxamniquine may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lind... |
DB00850 | DB00938 | 1,630 | 455 | [
"DDInter1432",
"DDInter1635"
] | Perphenazine | Salmeterol | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1630,
24,
455
]
],
[
[
1630,
24,
688
],
[
688,
63,
455
]
],
[
[
1630,
6,
8374
],
[
8374,
45,
455
]
],
[
[
1630,
7,
9650
],
[
9650,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Perphenazine (... |
DB00451 | DB00682 | 542 | 126 | [
"DDInter1064",
"DDInter1951"
] | Levothyroxine | Warfarin | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
542,
24,
126
]
],
[
[
542,
63,
362
],
[
362,
24,
126
]
],
[
[
542,
6,
3486
],
[
3486,
45,
126
]
],
[
[
542,
7,
2384
],
[
2384,
4... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Levothyroxine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Levothyroxine (Com... |
DB01394 | DB08875 | 1,554 | 1,618 | [
"DDInter431",
"DDInter262"
] | Colchicine | Cabozantinib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1554,
25,
1618
]
],
[
[
1554,
63,
112
],
[
112,
23,
1618
]
],
[
[
1554,
64,
723
],
[
723,
24,
1618
]
],
[
[
1554,
25,
384
],
[
384,
... | [
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metro... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Colchicine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may ... |
DB00039 | DB01041 | 1,253 | 770 | [
"DDInter1380",
"DDInter1789"
] | Palifermin | Thalidomide | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1253,
24,
770
]
],
[
[
1253,
24,
1668
],
[
1668,
1,
770
]
],
[
[
1253,
24,
4
],
[
4,
63,
770
]
],
[
[
1253,
24,
168
],
[
168,
24... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may caus... |
DB01276 | DB01583 | 123 | 624 | [
"DDInter706",
"DDInter1075"
] | Exenatide | Liotrix | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
123,
24,
624
]
],
[
[
123,
63,
1152
],
[
1152,
1,
624
]
],
[
[
123,
63,
542
],
[
542,
40,
624
]
],
[
[
123,
63,
417
],
[
417,
23... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound... |
DB00196 | DB00694 | 600 | 51 | [
"DDInter743",
"DDInter485"
] | Fluconazole | Daunorubicin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
600,
24,
51
]
],
[
[
600,
6,
4973
],
[
4973,
45,
51
]
],
[
[
600,
7,
14690
],
[
14690,
46,
51
]
],
[
[
600,
18,
6718
],
[
6718,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Daunorubicin (Compound)
Fluconazole (Compound) upregulates ABHD6 (Gene) and ABHD6 (Gene) is upregulated by Daunorubicin (Compound)
Fluconazole (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Daunorubicin (Compound)
Flucona... |
DB00041 | DB00631 | 1,648 | 372 | [
"DDInter38",
"DDInter405"
] | Aldesleukin | Clofarabine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1648,
24,
372
]
],
[
[
1648,
25,
1064
],
[
1064,
25,
372
]
],
[
[
1648,
24,
1488
],
[
1488,
40,
372
]
],
[
[
1648,
23,
1467
],
[
1467,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladrib... | Aldesleukin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles... |
DB08880 | DB14004 | 1,510 | 398 | [
"DDInter1771",
"DDInter1806"
] | Teriflunomide | Tildrakizumab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Major | 2 | [
[
[
1510,
25,
398
]
],
[
[
1510,
23,
1114
],
[
1114,
23,
398
]
],
[
[
1510,
62,
1461
],
[
1461,
23,
398
]
],
[
[
1510,
64,
58
],
[
58,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Z... | Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and ... |
DB13928 | DB14731 | 1,385 | 1,518 | [
"DDInter1660",
"DDInter1741"
] | Semaglutide | Tagraxofusp | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
1385,
24,
1518
]
],
[
[
1385,
63,
176
],
[
176,
24,
1518
]
],
[
[
1385,
63,
695
],
[
695,
25,
1518
]
],
[
[
1385,
63,
176
],
[
176,
... | [
[
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],... | Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Clozap... |
DB00277 | DB11767 | 1,031 | 1,583 | [
"DDInter1791",
"DDInter1643"
] | Theophylline | Sarilumab | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
1031,
24,
1583
]
],
[
[
1031,
63,
362
],
[
362,
24,
1583
]
],
[
[
1031,
24,
1627
],
[
1627,
24,
1583
]
],
[
[
1031,
23,
1382
],
[
1382... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cann... |
DB00804 | DB06691 | 1,507 | 849 | [
"DDInter543",
"DDInter1155"
] | Dicyclomine | Mepyramine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1507,
24,
849
]
],
[
[
1507,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1507,
24,
272
],
[
272,
24,
849
]
],
[
[
1507,
24,
1116
],
[
1116,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB00193 | DB00526 | 534 | 1,555 | [
"DDInter1841",
"DDInter1355"
] | Tramadol | Oxaliplatin | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
534,
24,
1555
]
],
[
[
534,
24,
79
],
[
79,
24,
1555
]
],
[
[
534,
1,
1100
],
[
1100,
24,
1555
]
],
[
[
534,
24,
1213
],
[
1213,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Tramadol (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could ex... |
DB00365 | DB14568 | 839 | 982 | [
"DDInter842",
"DDInter1000"
] | Grepafloxacin | Ivosidenib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
839,
25,
982
]
],
[
[
839,
23,
112
],
[
112,
23,
982
]
],
[
[
839,
62,
1101
],
[
1101,
23,
982
]
],
[
[
839,
24,
543
],
[
543,
2... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and ... |
DB00333 | DB06176 | 576 | 1,342 | [
"DDInter1166",
"DDInter1616"
] | Methadone | Romidepsin | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
576,
25,
1342
]
],
[
[
576,
23,
112
],
[
112,
23,
1342
]
],
[
[
576,
25,
485
],
[
485,
24,
1342
]
],
[
[
576,
25,
1616
],
[
1616,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Methadone may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may caus... |
DB01114 | DB09065 | 272 | 760 | [
"DDInter362",
"DDInter424"
] | Chlorpheniramine | Cobicistat | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
272,
24,
760
]
],
[
[
272,
63,
479
],
[
479,
23,
760
]
],
[
[
272,
24,
1627
],
[
1627,
23,
760
]
],
[
[
272,
63,
523
],
[
523,
2... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol a... |
DB01044 | DB08865 | 246 | 1,593 | [
"DDInter809",
"DDInter448"
] | Gatifloxacin | Crizotinib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
246,
25,
1593
]
],
[
[
246,
7,
7310
],
[
7310,
46,
1593
]
],
[
[
246,
18,
6735
],
[
6735,
46,
1593
]
],
[
[
246,
18,
4729
],
[
4729,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL9"
],
[
"KLHL9",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Gatifloxacin (Compound) upregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Crizotinib (Compound)
Gatifloxacin (Compound) downregulates BNIP3L (Gene) and BNIP3L (Gene) is upregulated by Crizotinib (Compound)
Gatifloxacin (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Crizotinib... |
DB01254 | DB11601 | 1,213 | 1,270 | [
"DDInter484",
"DDInter1889"
] | Dasatinib | Tuberculin purified protein derivative | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1213,
24,
1270
]
],
[
[
1213,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1213,
63,
869
],
[
869,
24,
1270
]
],
[
[
1213,
64,
1064
],
[
1064... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Dasatinib may cause a moderate interaction that could exacerbate diseases when take... |
DB00831 | DB01377 | 1,178 | 1,283 | [
"DDInter1866",
"DDInter1119"
] | Trifluoperazine | Magnesium oxide | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1178,
23,
1283
]
],
[
[
1178,
1,
684
],
[
684,
23,
1283
]
],
[
[
1178,
63,
167
],
[
167,
23,
1283
]
],
[
[
1178,
35,
104
],
[
104,
... | [
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} ma... | Trifluoperazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor ... |
DB00710 | DB11348 | 1,199 | 1,065 | [
"DDInter897",
"DDInter279"
] | Ibandronate | Calcium Phosphate | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1199,
24,
1065
]
],
[
[
1199,
1,
1008
],
[
1008,
24,
1065
]
],
[
[
1199,
40,
1485
],
[
1485,
24,
1065
]
],
[
[
1199,
1,
1008
],
[
1008... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} ... | Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate disease... |
DB00400 | DB08816 | 353 | 578 | [
"DDInter843",
"DDInter1802"
] | Griseofulvin | Ticagrelor | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
353,
24,
578
]
],
[
[
353,
6,
8374
],
[
8374,
45,
578
]
],
[
[
353,
21,
28762
],
[
28762,
60,
578
]
],
[
[
353,
24,
907
],
[
907,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Griseofulvin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and ... |
DB01764 | DB12500 | 805 | 283 | [
"DDInter469",
"DDInter714"
] | Dalfopristin | Fedratinib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Minor | 0 | [
[
[
805,
23,
283
]
],
[
[
805,
23,
466
],
[
466,
62,
283
]
],
[
[
805,
24,
351
],
[
351,
23,
283
]
],
[
[
805,
63,
1419
],
[
1419,
2... | [
[
[
"Dalfopristin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ri... |
DB00629 | DB01143 | 390 | 923 | [
"DDInter844",
"DDInter65"
] | Guanabenz | Amifostine | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
390,
24,
923
]
],
[
[
390,
21,
28642
],
[
28642,
60,
923
]
],
[
[
390,
1,
1364
],
[
1364,
24,
923
]
],
[
[
390,
24,
714
],
[
714,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Guanabenz",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} ... | Guanabenz (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Guanabenz (Compound) resembles Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Guanabenz may cause a moderate interaction that could ... |
DB00023 | DB00445 | 305 | 322 | [
"DDInter127",
"DDInter655"
] | Asparaginase Escherichia coli | Epirubicin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
305,
24,
322
]
],
[
[
305,
24,
1247
],
[
1247,
62,
322
]
],
[
[
305,
24,
1648
],
[
1648,
24,
322
]
],
[
[
305,
24,
671
],
[
671,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbat... |
DB00313 | DB06691 | 556 | 849 | [
"DDInter1913",
"DDInter1155"
] | Valproic acid | Mepyramine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
556,
24,
849
]
],
[
[
556,
24,
1594
],
[
1594,
24,
849
]
],
[
[
556,
6,
5918
],
[
5918,
45,
849
]
],
[
[
556,
24,
407
],
[
407,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Valproic acid (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is bound by Mepyramine (Compound)
Valproic a... |
DB00193 | DB00738 | 534 | 485 | [
"DDInter1841",
"DDInter1420"
] | Tramadol | Pentamidine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
534,
24,
485
]
],
[
[
534,
6,
12523
],
[
12523,
45,
485
]
],
[
[
534,
18,
4187
],
[
4187,
46,
485
]
],
[
[
534,
21,
29097
],
[
29097,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Tramadol (Compound) downregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Pentamidine (Compound)
Tramadol (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Pentamidine (Compound)
Tra... |
DB00365 | DB11986 | 839 | 484 | [
"DDInter842",
"DDInter648"
] | Grepafloxacin | Entrectinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
839,
25,
484
]
],
[
[
839,
23,
112
],
[
112,
23,
484
]
],
[
[
839,
25,
774
],
[
774,
24,
484
]
],
[
[
839,
24,
510
],
[
510,
24,... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Me... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Grepafloxacin may lead to a major life threatening interaction when taken with Degarelix and Degarelix may... |
DB00553 | DB00903 | 92 | 1,680 | [
"DDInter1177",
"DDInter686"
] | Methoxsalen | Etacrynic acid | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
92,
24,
1680
]
],
[
[
92,
21,
28882
],
[
28882,
60,
1680
]
],
[
[
92,
24,
1545
],
[
1545,
23,
1680
]
],
[
[
92,
24,
1669
],
[
1669,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Methoxsalen",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature incr... | Methoxsalen (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Etacrynic acid (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a minor interaction that ca... |
DB04868 | DB14443 | 478 | 987 | [
"DDInter1293",
"DDInter1931"
] | Nilotinib | Vibrio cholerae CVD 103-HgR strain live antigen | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
478,
24,
987
]
],
[
[
478,
24,
1468
],
[
1468,
24,
987
]
],
[
[
478,
64,
1220
],
[
1220,
24,
987
]
],
[
[
478,
25,
351
],
[
351,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Nilotinib may lead to a major life threatening interaction when taken with Dex... |
DB00470 | DB01089 | 530 | 1,340 | [
"DDInter601",
"DDInter502"
] | Dronabinol | Deserpidine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
530,
24,
1340
]
],
[
[
530,
63,
1245
],
[
1245,
40,
1340
]
],
[
[
530,
24,
1264
],
[
1264,
63,
1340
]
],
[
[
530,
24,
1376
],
[
1376,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacer... |
DB00773 | DB06317 | 896 | 1,626 | [
"DDInter702",
"DDInter630"
] | Etoposide | Elotuzumab | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
896,
24,
1626
]
],
[
[
896,
24,
973
],
[
973,
24,
1626
]
],
[
[
896,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
896,
24,
200
],
[
200,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastat... |
DB06589 | DB11791 | 1,250 | 785 | [
"DDInter1400",
"DDInter287"
] | Pazopanib | Capmatinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1250,
24,
785
]
],
[
[
1250,
64,
837
],
[
837,
23,
785
]
],
[
[
1250,
23,
1135
],
[
1135,
23,
785
]
],
[
[
1250,
63,
1324
],
[
1324,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazo... | Pazopanib may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a mi... |
DB00191 | DB01403 | 73 | 9 | [
"DDInter1447",
"DDInter1175"
] | Phentermine | Methotrimeprazine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
73,
24,
9
]
],
[
[
73,
24,
1178
],
[
1178,
40,
9
]
],
[
[
73,
24,
1164
],
[
1164,
1,
9
]
],
[
[
73,
24,
401
],
[
401,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles... |
DB00445 | DB00867 | 322 | 1,052 | [
"DDInter655",
"DDInter1606"
] | Epirubicin | Ritodrine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
322,
24,
1052
]
],
[
[
322,
24,
1523
],
[
1523,
40,
1052
]
],
[
[
322,
7,
5999
],
[
5999,
46,
1052
]
],
[
[
322,
18,
2183
],
[
2183,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ritodrine (Compound)
Epirubicin (Compound) upregulates DYRK3 (Gene) and DYRK3 (Gene) is upregulated by Ritodrine (Compound)
Epirubicin (Compound) downregulates CDC20 (Gene) and CDC20 (... |
DB00092 | DB01005 | 58 | 995 | [
"DDInter40",
"DDInter894"
] | Alefacept | Hydroxyurea | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
58,
24,
995
]
],
[
[
58,
24,
1238
],
[
1238,
24,
995
]
],
[
[
58,
24,
869
],
[
869,
63,
995
]
],
[
[
58,
63,
1648
],
[
1648,
24,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topote... |
DB00366 | DB00427 | 1,594 | 1,233 | [
"DDInter600",
"DDInter1879"
] | Doxylamine | Triprolidine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
1594,
24,
1233
]
],
[
[
1594,
6,
10104
],
[
10104,
45,
1233
]
],
[
[
1594,
24,
686
],
[
686,
63,
1233
]
],
[
[
1594,
24,
536
],
[
536,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Doxylamine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
... | Doxylamine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Triprolidine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Oxazepam and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Doxylamine may cause a... |
DB00681 | DB01021 | 1,287 | 674 | [
"DDInter85",
"DDInter1861"
] | Amphotericin B | Trichlormethiazide | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1287,
24,
674
]
],
[
[
1287,
63,
1014
],
[
1014,
40,
674
]
],
[
[
1287,
24,
178
],
[
178,
1,
674
]
],
[
[
1287,
24,
1577
],
[
1577,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazid... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resemble... |
DB00673 | DB08865 | 723 | 1,593 | [
"DDInter112",
"DDInter448"
] | Aprepitant | Crizotinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
723,
24,
1593
]
],
[
[
723,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
723,
21,
28771
],
[
28771,
60,
1593
]
],
[
[
723,
23,
307
],
[
307,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Aprepitant (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with M... |
DB01221 | DB09054 | 1,190 | 384 | [
"DDInter1007",
"DDInter905"
] | Ketamine | Idelalisib | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1190,
24,
384
]
],
[
[
1190,
63,
222
],
[
222,
23,
384
]
],
[
[
1190,
24,
1040
],
[
1040,
24,
384
]
],
[
[
1190,
24,
1619
],
[
1619,
... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib... |
DB00704 | DB01015 | 267 | 1,247 | [
"DDInter1263",
"DDInter1724"
] | Naltrexone | Sulfamethoxazole | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Moderate | 1 | [
[
[
267,
24,
1247
]
],
[
[
267,
63,
1029
],
[
1029,
1,
1247
]
],
[
[
267,
24,
698
],
[
698,
1,
1247
]
],
[
[
267,
21,
28804
],
[
28804,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
],... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfadoxine and Sulfadoxine (Compound) resembles Sulfamet... |
DB00321 | DB00902 | 21 | 104 | [
"DDInter78",
"DDInter1168"
] | Amitriptyline | Methdilazine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
21,
24,
104
]
],
[
[
21,
1,
11299
],
[
11299,
40,
104
]
],
[
[
21,
35,
13
],
[
13,
24,
104
]
],
[
[
21,
1,
11233
],
[
11233,
1,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Epinastine"
],
[
"Epinastine",
"{u} (Compound) ... | Amitriptyline (Compound) resembles Epinastine (Compound) and Epinastine (Compound) resembles Methdilazine (Compound)
Amitriptyline (Compound) resembles Cyproheptadine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause ... |
DB00836 | DB09065 | 543 | 760 | [
"DDInter1088",
"DDInter424"
] | Loperamide | Cobicistat | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
543,
25,
760
]
],
[
[
543,
24,
479
],
[
479,
23,
760
]
],
[
[
543,
63,
1230
],
[
1230,
23,
760
]
],
[
[
543,
25,
1374
],
[
1374,
... | [
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram... |
DB01156 | DB11943 | 593 | 255 | [
"DDInter252",
"DDInter495"
] | Bupropion | Delafloxacin | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Major | 2 | [
[
[
593,
25,
255
]
],
[
[
593,
63,
372
],
[
372,
23,
255
]
],
[
[
593,
25,
1053
],
[
1053,
23,
255
]
],
[
[
593,
64,
1648
],
[
1648,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabi... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Bupropion may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may ca... |
DB00350 | DB00679 | 1,214 | 684 | [
"DDInter1226",
"DDInter1796"
] | Minoxidil | Thioridazine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Moderate | 1 | [
[
[
1214,
24,
684
]
],
[
[
1214,
24,
1237
],
[
1237,
40,
684
]
],
[
[
1214,
24,
216
],
[
216,
1,
684
]
],
[
[
1214,
24,
1614
],
[
1614,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazi... |
DB09098 | DB12141 | 98 | 971 | [
"DDInter1700",
"DDInter817"
] | Somatrem | Gilteritinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
98,
24,
971
]
],
[
[
98,
63,
1135
],
[
1135,
23,
971
]
],
[
[
98,
24,
466
],
[
466,
62,
971
]
],
[
[
98,
63,
700
],
[
700,
24,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutami... |
DB00480 | DB11718 | 1,668 | 927 | [
"DDInter1035",
"DDInter640"
] | Lenalidomide | Encorafenib | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1668,
24,
927
]
],
[
[
1668,
24,
372
],
[
372,
24,
927
]
],
[
[
1668,
1,
770
],
[
770,
24,
927
]
],
[
[
1668,
64,
1463
],
[
1463,
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction t... |
DB01177 | DB06674 | 77 | 908 | [
"DDInter904",
"DDInter837"
] | Idarubicin | Golimumab | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
77,
25,
908
]
],
[
[
77,
63,
1461
],
[
1461,
23,
908
]
],
[
[
77,
63,
336
],
[
336,
24,
908
]
],
[
[
77,
24,
200
],
[
200,
63,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine ... |
DB01200 | DB01501 | 469 | 1,118 | [
"DDInter243",
"DDInter549"
] | Bromocriptine | Difenoxin | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
469,
24,
1118
]
],
[
[
469,
63,
1688
],
[
1688,
40,
1118
]
],
[
[
469,
63,
506
],
[
506,
24,
1118
]
],
[
[
469,
24,
1609
],
[
1609,
... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate... |
DB00555 | DB01114 | 706 | 272 | [
"DDInter1020",
"DDInter362"
] | Lamotrigine | Chlorpheniramine | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
706,
24,
272
]
],
[
[
706,
24,
849
],
[
849,
63,
272
]
],
[
[
706,
63,
128
],
[
128,
24,
272
]
],
[
[
706,
21,
28705
],
[
28705,
... | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenir... |
DB06674 | DB11627 | 908 | 1,367 | [
"DDInter837",
"DDInter860"
] | Golimumab | Hepatitis B Vaccine (Recombinant) | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
908,
24,
1367
]
],
[
[
908,
64,
1083
],
[
1083,
24,
1367
]
],
[
[
908,
25,
1480
],
[
1480,
24,
1367
]
],
[
[
908,
25,
119
],
[
119,
... | [
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
... | Golimumab may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Golimumab may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may ... |
DB00366 | DB00842 | 1,594 | 686 | [
"DDInter600",
"DDInter1359"
] | Doxylamine | Oxazepam | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Moderate | 1 | [
[
[
1594,
24,
686
]
],
[
[
1594,
63,
695
],
[
695,
40,
686
]
],
[
[
1594,
24,
1563
],
[
1563,
40,
686
]
],
[
[
1594,
24,
1119
],
[
1119,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Oxazepam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam (Compound) resembles Oxazepam (Compound)
Doxylami... |
DB01602 | DB09154 | 339 | 1,475 | [
"DDInter159",
"DDInter1686"
] | Bacampicillin | Sodium citrate | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal ac... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
339,
24,
1475
]
],
[
[
339,
64,
663
],
[
663,
23,
1475
]
],
[
[
339,
63,
1096
],
[
1096,
24,
1475
]
],
[
[
339,
24,
115
],
[
115,
... | [
[
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Bacampicillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
... | Bacampicillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and My... |
DB09292 | DB12015 | 1,202 | 1,033 | [
"DDInter1630",
"DDInter53"
] | Sacubitril | Alpelisib | Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015. Sacubitril'... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1202,
24,
1033
]
],
[
[
1202,
63,
760
],
[
760,
24,
1033
]
],
[
[
1202,
63,
760
],
[
760,
64,
1135
],
[
1135,
23,
1033
]
],
[
[
1202,
... | [
[
[
"Sacubitril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Sacubitril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
... | Sacubitril may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sacubitril may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicis... |
DB00629 | DB01088 | 390 | 714 | [
"DDInter844",
"DDInter908"
] | Guanabenz | Iloprost | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
390,
24,
714
]
],
[
[
390,
63,
1648
],
[
1648,
24,
714
]
],
[
[
390,
24,
1450
],
[
1450,
63,
714
]
],
[
[
390,
1,
1364
],
[
1364,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empag... |
DB00471 | DB00607 | 201 | 1,249 | [
"DDInter1242",
"DDInter1256"
] | Montelukast | Nafcillin | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Moderate | 1 | [
[
[
201,
24,
1249
]
],
[
[
201,
6,
8374
],
[
8374,
45,
1249
]
],
[
[
201,
21,
28792
],
[
28792,
60,
1249
]
],
[
[
201,
63,
1101
],
[
1101,... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nafcillin (Compound)
Montelukast (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases wh... |
DB06699 | DB08868 | 774 | 1,011 | [
"DDInter493",
"DDInter737"
] | Degarelix | Fingolimod | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
774,
25,
1011
]
],
[
[
774,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
774,
62,
1247
],
[
1247,
23,
1011
]
],
[
[
774,
24,
144
],
[
144,
... | [
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Degarelix",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side ... | Degarelix (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit cl... |
DB00446 | DB08930 | 597 | 1,459 | [
"DDInter351",
"DDInter582"
] | Chloramphenicol | Dolutegravir | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
597,
23,
1459
]
],
[
[
597,
21,
28722
],
[
28722,
60,
1459
]
],
[
[
597,
24,
478
],
[
478,
23,
1459
]
],
[
[
597,
25,
1478
],
[
1478,
... | [
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is ... | Chloramphenicol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dolutegravir (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Dolut... |
DB09343 | DB11730 | 750 | 351 | [
"DDInter1816",
"DDInter1588"
] | Tipiracil | Ribociclib | Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
750,
24,
351
]
],
[
[
750,
63,
752
],
[
752,
24,
351
]
],
[
[
750,
24,
1619
],
[
1619,
64,
351
]
],
[
[
750,
63,
1593
],
[
1593,
... | [
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Tipiracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Tipiracil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib... |
DB00072 | DB05679 | 550 | 1,683 | [
"DDInter1846",
"DDInter1907"
] | Trastuzumab | Ustekinumab | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
550,
24,
1683
]
],
[
[
550,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
550,
24,
126
],
[
126,
24,
1683
]
],
[
[
550,
25,
77
],
[
77,
... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin ... |
DB00604 | DB00701 | 1,425 | 1,091 | [
"DDInter385",
"DDInter90"
] | Cisapride | Amprenavir | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Amprenavir is a protease inhibitor used to treat HIV infection. | Major | 2 | [
[
[
1425,
25,
1091
]
],
[
[
1425,
25,
34
],
[
34,
1,
1091
]
],
[
[
1425,
6,
10215
],
[
10215,
45,
1091
]
],
[
[
1425,
64,
600
],
[
600,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{... | Cisapride may lead to a major life threatening interaction when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Cisapride (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Amprenavir (Compound)
Cisapride may lead to a major life threatening interaction when taken with ... |
DB01166 | DB06699 | 477 | 774 | [
"DDInter379",
"DDInter493"
] | Cilostazol | Degarelix | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
477,
24,
774
]
],
[
[
477,
63,
521
],
[
521,
1,
774
]
],
[
[
477,
21,
29232
],
[
29232,
60,
774
]
],
[
[
477,
62,
112
],
[
112,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Cilostazol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Cilostazol may cause a minor interaction that ca... |
DB00622 | DB01240 | 1,081 | 885 | [
"DDInter1287",
"DDInter657"
] | Nicardipine | Epoprostenol | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1081,
24,
885
]
],
[
[
1081,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1081,
6,
6017
],
[
6017,
45,
885
]
],
[
[
1081,
21,
28684
],
[
28684,... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Nicardipine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Nicardipine (Compound) causes Hypoaesthesia (Side Effect... |
DB00582 | DB06772 | 1,622 | 310 | [
"DDInter1946",
"DDInter259"
] | Voriconazole | Cabazitaxel | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1622,
24,
310
]
],
[
[
1622,
24,
973
],
[
973,
24,
310
]
],
[
[
1622,
6,
7524
],
[
7524,
45,
310
]
],
[
[
1622,
21,
28692
],
[
28692,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Voriconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Voriconazole... |
DB00934 | DB06691 | 413 | 849 | [
"DDInter1124",
"DDInter1155"
] | Maprotiline | Mepyramine | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
413,
24,
849
]
],
[
[
413,
63,
1594
],
[
1594,
24,
849
]
],
[
[
413,
24,
272
],
[
272,
24,
849
]
],
[
[
413,
6,
12523
],
[
12523,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB00687 | DB01265 | 870 | 1,477 | [
"DDInter747",
"DDInter1757"
] | Fludrocortisone | Telbivudine | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
870,
24,
1477
]
],
[
[
870,
63,
139
],
[
139,
1,
1477
]
],
[
[
870,
21,
28698
],
[
28698,
60,
1477
]
],
[
[
870,
1,
1220
],
[
1220,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Fludrocortisone (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Telbivudine (Compound)
Fludrocortisone (Compound) resembl... |
DB00860 | DB01226 | 891 | 1,319 | [
"DDInter1513",
"DDInter1235"
] | Prednisolone | Mivacurium | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Moderate | 1 | [
[
[
891,
24,
1319
]
],
[
[
891,
24,
648
],
[
648,
1,
1319
]
],
[
[
891,
21,
28921
],
[
28921,
60,
1319
]
],
[
[
891,
63,
1031
],
[
1031,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Prednisolone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mivacurium (Compound)
Prednisolone may cause a moderate intera... |
DB00250 | DB00468 | 10 | 1,424 | [
"DDInter475",
"DDInter1557"
] | Dapsone | Quinine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
10,
24,
1424
]
],
[
[
10,
5,
11571
],
[
11571,
44,
1424
]
],
[
[
10,
6,
21998
],
[
21998,
45,
1424
]
],
[
[
10,
21,
29169
],
[
29169,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Dapsone",
"{u} (Compound) treats {v} (Disease)",
"malaria"
],
[
"malaria",
"{u} (Disease) is treated by {v} (Compound)... | Dapsone (Compound) treats malaria (Disease) and malaria (Disease) is treated by Quinine (Compound)
Dapsone (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Quinine (Compound)
Dapsone (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Quinine (Compound)
Dapsone... |
DB00757 | DB13139 | 1,166 | 1,032 | [
"DDInter581",
"DDInter1063"
] | Dolasetron | Levosalbutamol | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1166,
24,
1032
]
],
[
[
1166,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1166,
64,
121
],
[
121,
24,
1032
]
],
[
[
1166,
25,
982
],
[
982,
... | [
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabo... | Dolasetron may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Dolasetron may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a m... |
DB01142 | DB11730 | 1,264 | 351 | [
"DDInter593",
"DDInter1588"
] | Doxepin | Ribociclib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1264,
25,
351
]
],
[
[
1264,
24,
271
],
[
271,
23,
351
]
],
[
[
1264,
62,
1247
],
[
1247,
23,
351
]
],
[
[
1264,
64,
222
],
[
222,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfametho... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.